retatrutide side effects clinical trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity Lilly orforglipron oral GLP-1 phase

This non-pharmacological therapy provides a safe and effective approach that improves disease outcomes by targeting the root cause

Tian, D., Chen, W., Xu, Q., Li, X., & Lv, Q

GLP-1 (glucagon-like peptide-1) receptor agonists have emerged as powerful tools in managing type 2 diabetes and obesity, offering significant benefits for weight reduction and metabolic health

In Singapore, individuals are generally classified as: Overweight: BMI 2327.4 Obese: BMI 27.5 Those who are overweight or obese may face an increased risk of: High blood pressure Obstructive sleep apnoea Insulin resistance and elevated blood sugar levels Singapore uses lower BMI cut-offs for overweight and obesity than many Western countries because Asians tend to develop excess body fat and obesity-related complications such as diabetes and cardiovascular disease at lower BMI levels

However, depending on how appetite, hydration, digestion, and food intake change over time, certain nutrients may become more difficult to maintain consistently through meals alone